Tim Miller, Forge Biologics CEO

Forge Bi­o­log­ics con­tin­ues its hot streak with $90M round to boost gene ther­a­py man­u­fac­tur­ing ser­vices

Over the past two years, the Ohio-based gene ther­a­py man­u­fac­tur­er Forge Bi­o­log­ics has man­aged to get a large amount of cap­i­tal to scale up its AAV pro­duc­tion ca­pa­bil­i­ties. And as the field con­tin­ues to grow, the com­pa­ny looks to grow along with it.

The com­pa­ny an­nounced Mon­day that it has raised $90 mil­lion in a Se­ries C fund­ing round, bring­ing the to­tal amount raised so far to $330 mil­lion. In an in­ter­view with End­points News, Forge Bi­o­log­ics CEO Tim Miller said that the round it­self took on­ly a few months to put to­geth­er as firms had ap­proached Forge to par­tic­i­pate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.